ExosomeRNP targeting PUMA ameliorated acute liver injury. ExosomeRNP targeting CcnE1 ameliorated chronic liver fibrosis. ExosomeRNP targeting KAT5 administered by tail vein injections ameliorated orthotopic hepatocellular carcinoma (HCC). This evidence concerns the gene KAT5 and hepatocellular carcinoma.